Log In
Print this Print this

Bcl-2 inhibitor

  Manage Alerts
Collapse Summary General Information
Company Ascentage Pharma Group Corp. Ltd.
DescriptionPan-Bcl-2 inhibitor
Molecular Target B cell lymphoma 2 (BCL-2) (BCL2)
Mechanism of ActionApoptosis inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC)
Regulatory Designation
Partner3SBio Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today